Evoke Pharma Stock Working Capital
| EVOK Stock | USD 2.80 0.00 0.00% |
Evoke Pharma fundamentals help investors to digest information that contributes to Evoke Pharma's financial success or failures. It also enables traders to predict the movement of Evoke Stock. The fundamental analysis module provides a way to measure Evoke Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evoke Pharma stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 6.9 M | 6.3 M | |
| Change In Working Capital | -1.4 M | -1.3 M |
Evoke | Working Capital |
Evoke Pharma Company Working Capital Analysis
Evoke Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Evoke Pharma Working Capital | 6.86 M |
Most of Evoke Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evoke Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Evoke Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Evoke Pharma is extremely important. It helps to project a fair market value of Evoke Stock properly, considering its historical fundamentals such as Working Capital. Since Evoke Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evoke Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evoke Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Evoke Capital Surpluse
Capital Surpluse |
|
According to the company's disclosures, Evoke Pharma has a Working Capital of 6.86 M. This is 98.39% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 99.54% higher than that of the company.
Evoke Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evoke Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evoke Pharma could also be used in its relative valuation, which is a method of valuing Evoke Pharma by comparing valuation metrics of similar companies.Evoke Pharma is currently under evaluation in working capital category among its peers.
Evoke Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evoke Pharma from analyzing Evoke Pharma's financial statements. These drivers represent accounts that assess Evoke Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evoke Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 65.8M | 17.7M | 8.4M | 3.5M | 6.2M | 5.9M | |
| Enterprise Value | 63.0M | 13.6M | 3.7M | 3.8M | (2.2M) | (2.1M) |
Evoke Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evoke Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evoke Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Evoke Fundamentals
| Return On Equity | -2.4 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.36) % | ||||
| Current Valuation | (3.56 M) | ||||
| Shares Outstanding | 1.49 M | ||||
| Shares Owned By Insiders | 5.02 % | ||||
| Shares Owned By Institutions | 14.63 % | ||||
| Number Of Shares Shorted | 43.87 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 0.47 X | ||||
| Revenue | 10.25 T | ||||
| Gross Profit | 9.89 M | ||||
| EBITDA | (5.2 T) | ||||
| Net Income | (5.35 T) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 160.49 B | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | 4.74 X | ||||
| Cash Flow From Operations | (5.46 T) | ||||
| Short Ratio | 4.18 X | ||||
| Earnings Per Share | (2.81) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 18.0 | ||||
| Beta | 0.12 | ||||
| Market Capitalization | 4.86 M | ||||
| Total Asset | 17.52 T | ||||
| Retained Earnings | (128.79 T) | ||||
| Working Capital | 6.86 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
| Net Asset | 17.52 T |
About Evoke Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evoke Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evoke Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evoke Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Evoke Pharma Piotroski F Score and Evoke Pharma Altman Z Score analysis. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share | Quarterly Revenue Growth 0.974 | Return On Assets | Return On Equity |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.